Incyte announces skin disease drug venture with Chinese company
Incyte and China Medical System Holdings Limited reached an agreement whereby Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of CMS (CMS Skinhealth), for the development and commercialization of povorcitinib. The agreement …